Dataset Information


The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.

ABSTRACT: Chronic myeloid leukemia (CML) is characterized by constitutively active fusion protein tyrosine kinase BCR-ABL. Although the tyrosine kinase inhibitor (TKI) against BCR-ABL, imatinib, is the first-line therapy for CML, acquired resistance almost inevitably emerges. The underlying mechanism are point mutations within the BCR-ABL gene, among which T315I is notorious because it resists to almost all currently available inhibitors. Here we took use of a previously generated chimeric ubiquitin ligase, SH2-U-box, in which SH2 from the adaptor protein Grb2 acts as a binding domain for activated BCR-ABL, while U-box from CHIP functions as an E3 ubiquitin ligase domain, so as to target the ubiquitination and degradation of both native and T315I-mutant BCR-ABL. As such, SH2-U-box significantly inhibited proliferation and induced apoptosis in CML cells harboring either the wild-type or T315I-mutant BCR-ABL (K562 or K562R), with BCR-ABL-dependent signaling pathways being repressed. Moreover, SH2-U-box worked in concert with imatinib in K562 cells. Importantly, SH2-U-box-carrying lentivirus could markedly suppress the growth of K562-xenografts in nude mice or K562R-xenografts in SCID mice, as well as that of primary CML cells. Collectively, by degrading the native and T315I-mutant BCR-ABL, the chimeric ubiquitin ligase SH2-U-box may serve as a potential therapy for both imatinib-sensitive and resistant CML.


PROVIDER: S-EPMC4916441 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3847136 | BioStudies
2017-01-01 | S-EPMC5515395 | BioStudies
2014-01-01 | S-EPMC4647898 | BioStudies
2014-01-01 | S-EPMC3938960 | BioStudies
1000-01-01 | S-EPMC2893099 | BioStudies
2012-01-01 | S-EPMC3361532 | BioStudies
2015-01-01 | S-EPMC4359310 | BioStudies
1000-01-01 | S-EPMC2481545 | BioStudies
2017-01-01 | S-EPMC6010122 | BioStudies
2013-01-01 | S-EPMC3568121 | BioStudies